Harvard Bioscience Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Harvard BioscienceDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -11.2% zurückgegangen, während in der Branche Life Sciences die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 0.4% pro Jahr.

Wichtige Informationen

-12.4%

Wachstumsrate der Gewinne

-9.3%

EPS-Wachstumsrate

Life Sciences Wachstum der Industrie	21.5%
Wachstumsrate der Einnahmen	-0.5%
Eigenkapitalrendite	-15.9%
Netto-Marge	-10.6%
Letzte Ertragsaktualisierung	30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Aug 07

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Jul 15

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28

Aufschlüsselung der Einnahmen und Ausgaben

Wie Harvard Bioscience Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:HBIO Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	101	-11	46	11
31 Mar 24	107	-9	46	12
31 Dec 23	112	-3	47	12
30 Sep 23	113	-3	47	11
30 Jun 23	114	-5	47	11
31 Mar 23	115	-2	48	12
31 Dec 22	113	-10	49	12
30 Sep 22	118	-7	51	12
30 Jun 22	121	-4	50	12
31 Mar 22	121	-6	49	12
31 Dec 21	119	0	47	11
30 Sep 21	117	-2	45	10
30 Jun 21	111	-3	43	9
31 Mar 21	105	-4	41	9
31 Dec 20	102	-8	41	9
30 Sep 20	102	-7	42	9
30 Jun 20	105	-8	44	10
31 Mar 20	112	-7	45	10
31 Dec 19	116	-5	46	11
30 Sep 19	119	-2	47	11
30 Jun 19	120	0	46	11
31 Mar 19	122	-1	47	11
31 Dec 18	121	-4	46	11
30 Sep 18	109	-8	42	9
30 Jun 18	99	-8	39	8
31 Mar 18	86	-7	35	7
31 Dec 17	77	-2	33	6
30 Sep 17	82	-3	34	5
30 Jun 17	88	-4	36	5
31 Mar 17	96	-4	39	5
31 Dec 16	105	-4	41	5
30 Sep 16	106	-20	41	6
30 Jun 16	107	-19	42	6
31 Mar 16	110	-18	41	6
31 Dec 15	109	-19	40	6
30 Sep 15	111	-2	40	6
30 Jun 15	110	0	38	6
31 Mar 15	109	0	36	6
31 Dec 14	109	2	35	5
30 Sep 14	106	2	34	4
30 Jun 14	106	1	35	4
31 Mar 14	105	1	35	4
31 Dec 13	105	1	35	4
30 Sep 13	106	4	34	2

Qualität der Erträge: HBIO ist derzeit unrentabel.

Wachsende Gewinnspanne: HBIO ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: HBIO ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 11.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von HBIO verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: HBIO ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Life Sciences (-6.5%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: HBIO hat eine negative Eigenkapitalrendite (-12.69%), da es derzeit unrentabel ist.

Harvard Bioscience Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Recent updates

Harvard Bioscience, Inc. to Showcase Latest Solutions for Preclinical and Organoid Applications At Safety Pharmacology Society Annual Meeting

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2024

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Harvard Bioscience, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story

Harvard Bioscience, Inc. Provides Earnings Guidance for the Full Year 2024

Harvard Bioscience, Inc. to Report Q1, 2024 Results on May 07, 2024

Harvard Bioscience, Inc. Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

Harvard Bioscience, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Full Year 2024

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications At Society of Toxicology Meeting

Harvard Bioscience, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. Provides Revenue Guidance for the Year 2023

Harvard Bioscience, Inc. to Showcase Latest Innovations in Preclinical and Organoid Research At Society for Neuroscience Conference

Harvard Bioscience, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

President recently bought US$110k worth of stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Harvard Bioscience, Inc. Provides Earnings Guidance for Full Year 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Harvard Bioscience, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Now 20% undervalued

Harvard Bioscience, Inc. Appoints Jennifer Cote as Chief Financial Officer

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

President recently bought US$105k worth of stock

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience, Inc. Announces CFO Changes

President recently bought US$75k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.082 loss per share (vs US$0.004 loss in 3Q 2021)

Harvard Bioscience, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought US$83k worth of stock

President recently bought US$128k worth of stock

Forecast breakeven date pushed back to 2023

Price target decreased to US$8.50

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Harvard Bioscience, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Harvard Bioscience, Inc.(NasdaqGM:HBIO) dropped from Russell 2000 Dynamic Index

President recently bought US$111k worth of stock

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

President recently bought US$147k worth of stock

Forecast breakeven date pushed back to 2023

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.017 loss in 1Q 2021)

Harvard Bioscience, Inc. Introduces Smartstudy™ First of Kind, Next Generation Inhalation System Capability Improves Precision and Drives Growth

Harvard Bioscience, Inc. to Report Q1, 2022 Results on May 04, 2022

Harvard Bioscience, Inc., Annual General Meeting, May 17, 2022

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Full year 2021 earnings: EPS misses analyst expectations

Harvard Bioscience, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Harvard Bioscience, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2022

Third quarter 2021 earnings released: US$0.004 loss per share (vs US$0.028 loss in 3Q 2020)

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

President recently sold US$386k worth of stock

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.041 loss in 2Q 2020)

Price target increased to US$9.67